Page last updated: 2024-09-03

gefitinib and zstk474

gefitinib has been researched along with zstk474 in 2 studies

Compound Research Comparison

Studies (gefitinib)	Trials (gefitinib)	Recent Studies (post-2010) (gefitinib)	Studies (zstk474)	Trials (zstk474)	Recent Studies (post-2010) (zstk474)
5,231	566	2,919	94	0	80

Protein Interaction Comparison

Protein	Taxonomy	zstk474 (IC50)
Chain A, PHOSPHATIDYLINOSITOL-4,5-BISPHOSPHATE 3-KINASE CATALYTIC SUBUNIT DELTA ISOFORM	Mus musculus (house mouse)	0.0046
Chain A, PHOSPHATIDYLINOSITOL-4,5-BISPHOSPHATE 3-KINASE CATALYTIC SUBUNIT DELTA ISOFORM	Mus musculus (house mouse)	0.0046
Chain A, PHOSPHATIDYLINOSITOL-4,5-BISPHOSPHATE 3-KINASE CATALYTIC SUBUNIT DELTA ISOFORM	Mus musculus (house mouse)	0.0046
Chain A, PHOSPHATIDYLINOSITOL-4,5-BISPHOSPHATE 3-KINASE CATALYTIC SUBUNIT DELTA ISOFORM	Mus musculus (house mouse)	0.0046
Chain A, PHOSPHATIDYLINOSITOL-4,5-BISPHOSPHATE 3-KINASE CATALYTIC SUBUNIT DELTA ISOFORM	Mus musculus (house mouse)	0.0046
Chain A, PHOSPHATIDYLINOSITOL-4,5-BISPHOSPHATE 3-KINASE CATALYTIC SUBUNIT DELTA ISOFORM	Mus musculus (house mouse)	0.0046
Chain A, PHOSPHATIDYLINOSITOL-4,5-BISPHOSPHATE 3-KINASE CATALYTIC SUBUNIT DELTA ISOFORM	Mus musculus (house mouse)	0.0046
Chain A, PHOSPHATIDYLINOSITOL-4,5-BISPHOSPHATE 3-KINASE CATALYTIC SUBUNIT DELTA ISOFORM	Mus musculus (house mouse)	0.0046
Chain A, PHOSPHATIDYLINOSITOL-4,5-BISPHOSPHATE 3-KINASE CATALYTIC SUBUNIT DELTA ISOFORM	Mus musculus (house mouse)	0.0046
Chain A, PHOSPHATIDYLINOSITOL-4,5-BISPHOSPHATE 3-KINASE CATALYTIC SUBUNIT DELTA ISOFORM	Mus musculus (house mouse)	0.0046
Chain A, PHOSPHATIDYLINOSITOL-4,5-BISPHOSPHATE 3-KINASE CATALYTIC SUBUNIT DELTA ISOFORM	Mus musculus (house mouse)	0.0046
Chain A, PHOSPHATIDYLINOSITOL-4,5-BISPHOSPHATE 3-KINASE CATALYTIC SUBUNIT DELTA ISOFORM	Mus musculus (house mouse)	0.0046
Chain A, PHOSPHATIDYLINOSITOL-4,5-BISPHOSPHATE 3-KINASE CATALYTIC SUBUNIT DELTA ISOFORM	Mus musculus (house mouse)	0.0046
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)	0.0105
Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit beta	Homo sapiens (human)	0.18
Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)	0.0049
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)	0.0218
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Mus musculus (house mouse)	0.0086
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)	0.0276
Serine/threonine-protein kinase mTOR	Homo sapiens (human)	0.3633
Serine/threonine-protein kinase mTOR	Rattus norvegicus (Norway rat)	0.045
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)	0.0369

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Atkey, N; Bolton, LM; Cree, IA; Dyson, M; Glaysher, S; Johnson, P; Torrance, C	1
Bolton, LM; Cree, IA; Glaysher, S; Johnson, P; Torrance, C	1

Other Studies

2 other study(ies) available for gefitinib and zstk474

Article	Year
Targeting EGFR and PI3K pathways in ovarian cancer. British journal of cancer, 2013, Oct-01, Volume: 109, Issue:7 Topics: Antibiotics, Antineoplastic; Cell Proliferation; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Ovarian Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Quinazolines; Sirolimus; Triazines; Tumor Cells, Cultured	2013
Activity of EGFR, mTOR and PI3K inhibitors in an isogenic breast cell line model. BMC research notes, 2014, Jun-25, Volume: 7 Topics: Breast; Cell Line; Cell Survival; Drug Synergism; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Mutation; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Quinazolines; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Triazines	2014

Article

Year

Targeting EGFR and PI3K pathways in ovarian cancer.

British journal of cancer, 2013, Oct-01, Volume: 109, Issue:7

Topics: Antibiotics, Antineoplastic; Cell Proliferation; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Ovarian Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Quinazolines; Sirolimus; Triazines; Tumor Cells, Cultured

2013

Activity of EGFR, mTOR and PI3K inhibitors in an isogenic breast cell line model.

BMC research notes, 2014, Jun-25, Volume: 7

Topics: Breast; Cell Line; Cell Survival; Drug Synergism; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Mutation; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Quinazolines; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Triazines

2014